Table 3.
Definitions of CR and PR in patients treated for AIHA
| Response | Definition | |
|---|---|---|
| CR (n = 24) | ||
| Hb > or ≥120 g/L (n = 10) | ||
| >120 | Plus Hb increase of at least 20 g/L above pretreatment Hb without transfusion or concomitant therapy (n = 1) | |
| > or ≥120 | Plus no laboratory features of hemolysis* (n = 4)† | |
| > or ≥120 | Plus no laboratory features of hemolysis | Plus independent from transfusion (n = 4)‡ |
| ≥120 | Plus no laboratory features of hemolysis and independent from transfusion | Plus on no medication except steroids at stable or reducing dose (n = 1) |
| Normalization of Hb (n = 9) | ||
| Normalization of Hb only (n = 1) | ||
| Normalization of Hb | Plus no laboratory features of hemolysis (n = 1) | |
| Plus no laboratory features of hemolysis | Plus no detectable antibodies in serum or eluate or on red cells (n = 2) | |
| Plus no laboratory features of hemolysis | Plus sustained for at least 6 mo (n = 1) | |
| Plus no laboratory features of hemolysis | Plus without ongoing immunosuppresion (n = 2) | |
| Plus no laboratory features of hemolysis | Plus no transfusion (n = 1) | |
| Plus no laboratory features of hemolysis | Plus independent from additional treatment (n = 1) | |
| Hb > or ≥110 g/L (n = 5) | ||
| >110 (n = 2) | ||
| ≥110 | Plus reticulocytes <120 × 109/L (irrespective of treatment or DAT) (n = 1) | |
| >110 | Plus reticulocytes <120 × 109/L for 4 wk | Plus no rescue or supportive regimens during that time (n = 1) |
| >110 (women) or 120 (men) | Plus no laboratory features of hemolysis | Plus not on treatment (n = 1) |
| PR (n = 24) | ||
| Minimum Hb 100 g/L (n = 9) | ||
| ≥100 or 100-120 or rise of at least 20 | Plus no transfusion (n = 2) | |
| ≥100 or rise of at least 20 | Plus absence of any treatment (n = 1) | |
| >100 or rise of at least 20 | Plus maintained for at least 6 mo posttreatment (n = 1) | |
| ≥100 and rise of at least 20 | Plus persistent hemolysis (n = 2) | |
| ≥100 and rise of at least 20 | Plus no transfusion (n = 1) | |
| ≥100 and rise of at least 20 | Plus without hemolysis or with hemolysis if Hb stable | Plus no medication except steroid at stable or reducing dose (n = 1) |
| ≥100 and rise of at least 20 | Plus persistent hemolysis | Plus no transfusion in last 2 wk and off treatment or stable dose of prednisolone at ≤10 mg (n = 1) |
| Minimum Hb 70-90 g/L (n = 5) | ||
| 90-110 (n = 1) | ||
| >80 but below normal (n = 1) | ||
| 80-110 or if baseline >80, then rise >15 (n = 1) | ||
| 70-110 ± reticulocytosis (>120 × 109/L) or >110 with reticulocytosis (n = 1) | ||
| 70-110 or >110 with reticulocytosis (>120 × 109/L) | Plus sustained during 4 consecutive wk without rescue or supportive care regimens (n = 1) | |
| No absolute minimum Hb (g/L) threshold (n = 10) | ||
| Increase of at least 20 and/or transfusion independence if previously dependent (n = 1) | ||
| Increase of at least 20 | Plus Hb <120 g/L ± persistent hemolysis (n = 1) | |
| Increase of at least 20 | Plus improved markers of hemolysis but Hb <120 g/L | Plus reduced transfusion (n = 1) |
| Hb increase of at least 20 g/L | Plus improved clinical and laboratory signs of hemolysis | Plus transfusion free or reduced requirements (n = 2) |
| Improvement in hemolysis markers but need for maintenance treatment (n = 1) | ||
| Improvement in laboratory markers or decrease in transfusion requirements but persistence of detectable antibodies (n = 2) | ||
| Improved clinical and laboratory analysis and/or steroid dependence despite presence of autoantibodies (n = 1) | ||
| CR except requiring maintenance prednisolone <10 mg/d or stable hemolysis with acceptable Hb without treatment except prednisolone <10 mg/d (n = 1) | ||
*
Laboratory assessment of hemolysis varied.
†
Irrespective of the DAT result (n = 1).
‡
Irrespective of the DAT result (n = 1).